A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
Titel:
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
Auteur:
Jarskog, L. Fredrik Lowy, Martin T. Grove, Richard A. Keefe, Richard S.E. Horrigan, Joseph P. Ball, M. Patricia Breier, Alan Buchanan, Robert W. Carter, Cameron S. Csernansky, John G. Goff, Donald C. Green, Michael F. Kantrowitz, Joshua T. Keshavan, Matcheri S. Laurelle, Marc Lieberman, Jeffrey A. Marder, Stephen R. Maruff, Paul McMahon, Robert P. Seidman, Larry J. Peykamian, Margaret A.